Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers

Diabetes Research and Clinical Practice

Volumn 49, Issue 2-3, 2000, Pages 119-126

  Kaku, Kohei ^a   Matsuda, Masafumi ^a   Urae, Akinori ^b   Irie, Shin ^c  

^a Kawasaki Medical School   (Japan)

^b Clinical Pharmacology Center   (Japan)

^c Kyushu Clinical Pharmacology Research Clinic   (Japan)

Author keywords

Insulin analog; Insulin aspart; Japanese; Pharmacodynamics; Pharmacokinetics

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; PENFIL R;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; JAPAN; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; METABOLIC CLEARANCE RATE; RADIOIMMUNOASSAY; SINGLE-BLIND METHOD;

EID: 0033839376     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(00)00151-0     Document Type: Article

References (24)

1. The effect of intensive treatment of diabetes on the development and the progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:1993;977-986.
2. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28:1995;103-117.
3. Eaton R.P., Allen R.C., Schade S., Standefer J.C. Normal insulin secretion: the goal of artificial insulin delivery systems? Diabetes Care. 3:1980;270-273.
4. Home P.D., Pickup J.C., Keen H., Alberti K.G.M.M., Parsons J.A., Binder C. Continuous subcutaneous insulin infusion: comparison of plasma insulin profiles after infusion or bolus injection of the mealtime dose. Metabolism. 30:1981;439-442.
5. Van Haeften T.W., Bolli G.B., Dimitridias G.D., Gottesman I.S., Horwitz D.L., Gerich J.E. Effect of insulin antibodies and their kinetic characteristics on plasma free insulin dynamics in patients with diabetes mellitus. Metabolism. 35:1986;649-656.
6. Berger M., Cuppers H.J., Hegner H., Jörgens V., Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care. 5:1982;77-91.
7. Blundell T., Dodson G., Hodglin D., Mercola D. Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv. Protein Chem. 26:1972;279-402.
8. Brange J., Owens D.R., Kang S., Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 13:1990;923-954.
9. Kang S., Brange J., Burch A., Vølund A., Owens D.R. Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9, GluB27, AspB10, AspB28) in healthy subjects. Diabetes Care. 14:1991;1057-1065.
10. Kang S., Creagh F.M., Peters J.R., Brange J., Vølund A., Owens D.R. Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27, AspB10, AspB28) on meal-related plasma glucose excursions in type 1 diabetic subjects. Diabetes Care. 14:1991;571-577.
11. Heinneman L., Heise T., Jorgensen L.N., Starke A.A.R. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabetic Med. 10:1993;535-539.
12. Wiefels K., Hübinger A., Dannebland K., Gries F.A. Insulinkinetic and-dynamic in diabetic patients under insulin pump therapy after injections of human insulin or insulin analogue (B28Asp). Horm. Metab. Res. 27:1995;421-424.
13. Heinneman L., Weyer C., Rauhaus M., Heinfichs S., Heise T. Variability of the metabolic ellect of soluble irmulin and the rapid-acting insulin analog insulin aspart. Diabetes Care. 21:1998;1910-1914.
14. Owens D.R. Clinical - pharmacological studies. Human Insulin - Clinical Pharmacological Studies in Normal Man. 1986;46-236 MTP Press, Lancaster, UK.
15. Home P.D., Barriocanal L., Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur. J. Clin. Pharmacol. 55:1999;199-203.
16. Home P.D., Lindholm A., Hylleberg B., Round P. Improved giycemic control with insulin aspart. A multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care. 21:1998;1904-1909.
17. Heinneman L., Weyer C., Rave K., Stiefelhagen O., Rauhaus M., Heise T. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28Asp. Exp. Clin. Endocrinol. Diabetes. 105:1997;140-144.
18. Lindholm A., McEwen J., Riis A.P. Improved postprandial glycemic control with insulin aspart - a randomized double-blind cross-over trial in type 1 diabetes mellitus. Diabetes Care. 22:1999;801-804.
19. Anderson J.H., Brunelle R.L., Koivisto V.A., Pfützner A., Trautmann M.E., Vignati L., DiMarchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 46:1997;265-270.
20. Joiner C.L. Rate of clearance of insulin labeled with 131I from the subcutaneous tissues in normal and diabetic subjects. Lancet. 1:1959;964-967.
21. Koivisto V.A., Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann. Intern. Med. 92:1980;59-61.
22. Vora J.P., Burch A., Peters J.R., Owens D.R.: Relationship between absorption of radio-labeled soluble insulin, subcutaneous blood flow, and anthropomely. Diabetes Care. 15:1992;1484-1493.
23. Mudahar S.R., Lindberg F.A., Joyce M., Beerdsen P., Strange P., Lin A., Henry R.R. Insulin aspart (B28Asp-insulin): a fast-acting analog of human insulin. Diabetes Care. 22:1999;1501-1506.
24. Howey D.C., Bowsher R.R., Brunelle R.L., Woodworth J.R. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 43:1994;396-402.